Skip to content

Goal-Directed Therapy Following Cardiac Surgery

Goal-Directed Therapy (GDT) Using Hypotension Prediction Index (HPI) Following Cardiac Surgery: a Pilot Randomized Control Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05964374
Enrollment
100
Registered
2023-07-27
Start date
2023-07-31
Completion date
2024-06-30
Last updated
2023-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery

Keywords

cardiac surgery, hemodynamic optimization, goal-directed therapy

Brief summary

Pilot prospective randomized control trial comparing goal-directed therapy algorithm vs routine care in the intensive care unit following cardiac surgery.

Detailed description

Rationale: Goal-directed therapy (GDT) has been shown to reduce complications and length of stay on cardiac surgery patients. Unfortunately, the existing literature on GDT in CV surgery has several limitations, which creates uncertainty over the expected benefit of implementing this care element with high associated costs and impact on workflow. Hypotension Prediction Index (HPI) is a proprietary algorithm that utilizes pulse contour analysis from invasive arterial pressure monitoring to identify patients at risk for becoming hypotensive within 15 minutes. The algorithm was developed using machine learning on a large surgical/ICU data set, and then externally validated on non-cardiac and cardiac surgical patients. HPI, as part of a GDT algorithm, may allow healthcare providers to identify patients recovering from cardiac surgery who may benefit from optimization prior to becoming hypotensive and assist with selecting the most appropriate hemodynamic intervention. Hypothesis: Application of an HPI-based GDT algorithm will result in a difference in cumulative fluid administration over the first 24-hours of index ICU admission following cardiac surgery. Study Design: Unblinded randomized controlled trial pilot. Data will be used to inform/justify the feasibility, design, and implementation of a future multi-center randomized controlled trial. Study Population: Moderate or high-risk (EuroSCORE II \> 2%), non-emergent, adult open-heart cardiac surgery patients. Heart transplant, durable VAD implantation, or patients who require post-operative MCS support will be excluded. Sample size= 100 (50 control : 50 intervention) Intervention: Patients randomized to the intervention arm will be monitored using the HPI technology and be treated following a GDT algorithm when HPI is \>50 for 48-hours or duration of invasive arterial monitoring (whichever occurs first). The GDT algorithm is a standardized approach to identifying abnormal hemodynamic parameters and administering a prescribed therapy in a step-wise fashion with fixed re-assessment intervals (see attached). What will be different from routine care? : 1. Hemodynamic interventions (fluid, inotropic, or vasopressor therapy) will be administered when HPI \> 50 rather than MAP \< 65. 2. Choice of applied therapy (fluid, inotropic, or vasopressor therapy) will be guided by a GDT algorithm.

Interventions

Goal-directed therapy using HemoSphere® monitor, Acumen® transducer, and Hypotension Prediction Index® algorithm (Edwards Lifesciences, Irvine, USA),

Sponsors

University of Alberta
CollaboratorOTHER
University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

1. ≥ 18 years of age 2. Planned cardiac surgery using cardiopulmonary bypass (sternotomy or MICS) 3. Preoperative European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) of 2% or more. 4. Informed consent obtained.

Exclusion criteria

1. Patients who refuse participation 2. Patients who are unable to give informed consent 3. Patients who are having a heart transplant or having surgery solely for an insertion of a ventricular assist device 4. Emergency surgery 5. Patients who require MCS (including ECMO, Impella, or IABP) post-operatively

Design outcomes

Primary

MeasureTime frameDescription
24-hour cumulative IV fluid administration24-hoursCumulative post-operative intravenous fluid administration over the first 24-hours of index ICU admission.

Secondary

MeasureTime frameDescription
Vasoactive medication administrationDuration of ICU stay, up to 30-daysDaily average
Hemodynamic parameters48-hours or when arterial line removedIncidence of HPI \> 50 greater than 5-minutes
Enrollment1-yearProportion of screened patients eligible for enrollment.
Study Protocol Compliance1-yearProportion of consented patients who complete all study assessments.
Arterial Monitoring Reliability1-yearNumber of arterial catheters requiring replacement
GDT algorithm compliance48-hours or when arterial line removedTime from HPI \> 50 to application of an intervention
End-organ dysfunction/injuryIndex admission, up to 30-daysAcute kidney injury
TransfusionIndex admission, up to 30-daysTotal red-blood cell administration
Fluid AdministrationDuration of ICU stay, up to 30-daysDaily average
MobilizationIndex admission, up to 30-daysTime to first mobilization (walk)
HydrationIndex admission, up to 30-daysTime to first PO hydration
NutritionIndex admission, up to 30-daysTime to first PO nutrition
Patient-centered OutcomeIndex admission, up to 10-daysQuality of Recovery-15 (QOR-15) at post-op days 3, 5, 7, and 10.
Length of StayUp to 1-year post-operativeICU length of stay
Re-admission30-daysIncidence of hospital re-admission within 30-days of index surgery
MortalityUp to 1-year post-operative7-day, 30-day, and 1-year mortality.
MobilzationIndex admission, up to 30-daysTime to first mobilization (dangle)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026